search
Back to results

Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT

Primary Purpose

Type 1 Diabetes, Type 2 Diabetes Treated With Insulin

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
GlucoSTAT
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 1 Diabetes focused on measuring closed loop, insulin, dextrose

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Type 1 diabetes:

  1. Age 18 years or older with clinical type 1 diabetes for at least one year.
  2. Diabetes currently managed using an insulin infusion pump and rapid- or very-rapid-acting insulins including insulin aspart (NovoLog or Fiasp), insulin lispro (Humalog), and insulin glulisine (Apidra).
  3. Total daily dose (TDD) of insulin that is ≤ 1 U/kg
  4. Prescription medication regimen stable for at least 1 month.
  5. Informed consent obtained before any trial-related activities.

Type 2 diabetes:

  1. Age 18 years or older with clinical type 2 diabetes for at least 1 year.
  2. Diabetes currently managed using NPH as the basal insulin, which may be supplemented with regular or rapid-acting insulin and/or other anti-diabetic drugs.
  3. Total daily dose (TDD) of insulin that is > 0.75 u/kg

    • Our goal is to have up to 3 T2D subjects with a TDD > 2 u/kg
  4. Prescription medication regimen stable for at least 1 month.
  5. Informed consent obtained before any trial-related activities.

Exclusion Criteria:

  1. Unable to provide informed consent.
  2. Unable to comply with study procedures.
  3. Current participation in another diabetes-related clinical trial that, in the judgement of the principal investigator, will compromise the results of this study or the safety of the participant
  4. Use of a long-acting insulin (in type 1 diabetes subjects) or a long-acting insulin other than NPH (in type 2 diabetes subjects), including insulin glargine (Lantus), insulin detemir (Levemir), insulin degludec (Tresiba), or ultra-lente.
  5. Pregnancy (positive urine HCG), breast feeding, plan to become pregnant in the immediate future, or sexually active without use of contraception.
  6. Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be susceptible to RF interference.
  7. Established history of latex, adhesive, or tape allergy that must be used in the study
  8. Inadequate venous access as determined by study nurse or physician at time of screening.
  9. Employed by, or having immediate family members employed by Beta Bionics, or being directly involved in conducting the clinical trial, or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial.
  10. A condition that in the opinion of the investigator could interfere with the safe completion of the study. Conditions to be considered by the investigator may include the following:

    • Alcohol or drug abuse
    • Use of prescription drugs that may dull the sensorium, reduce sensitivity to symptoms of hypoglycemia, or hinder decision making during the period of participation in the study
    • Renal failure
    • Coronary artery disease that is not stable with medical management, including unstable angina, angina that prevents moderate exercise (e.g. climbing a flight of stairs) despite medical management, or within the last 12 months before screening a history of myocardial infarction, percutaneous coronary intervention, enzymatic lysis of a presumed coronary occlusion, or coronary artery bypass grafting
    • Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV
    • History of TIA or stroke in the last 12 months
    • Untreated or inadequately treated mental illness

Sites / Locations

  • Massachusetts General Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

GlucoSTAT

Arm Description

Type 1 diabetes and Type 2 diabetes with a total daily dose (TDD) of insulin that is > 0.75 u/kg or ≥ 2 u/kg.

Outcomes

Primary Outcome Measures

Average plasma glucose over the closed-loop control period
Average plasma glucose

Secondary Outcome Measures

Number of carbohydrate interventions needed to treat hypoglycemia
The number of times that carbohydrates were consumed in response to hypoglycemia throughout the 8.5 hour experiment
Grams of carbohydrates needed to treat hypoglycemia
The amount of carbohydrates consumed in response to hypoglycemia throughout the 8.5 hour experiment
Carbohydrate content and total calories of consumed lunch meal
The amount of carbohydrates and total calories the subject consumed during their provided lunch
Insulin dosing (u/kg)
Total amount of insulin delivered by the GlucoSTAT during the experiment
Dextrose dosing (g/kg)
Total amount of dextrose delivered by the GlucoSTAT during the experiment

Full Information

First Posted
January 10, 2020
Last Updated
October 19, 2020
Sponsor
Massachusetts General Hospital
Collaborators
Beta Bionics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04227626
Brief Title
Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT
Official Title
A Feasibility Study of Automated Glucose Control With the Gen2 GlucoSTAT Bionic Pancreas in Volunteers With Type 1 and Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Withdrawn
Why Stopped
The study has not started, the device is not ready so the study will be delayed
Study Start Date
April 2021 (Anticipated)
Primary Completion Date
April 2021 (Anticipated)
Study Completion Date
April 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
Beta Bionics, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this study is to perform a first-in-humans trial of a fully integrated, automated, closed-loop blood glucose control system designed for inpatient use. The GlucoSTAT was designed for use by patients with diabetes while they are in the hospital, and others who may develop high blood sugar as a result of their medical problems.
Detailed Description
Our envisioned end product is an in-patient automated closed-loop control system for PG regulation in the ICU as well as on the general hospital wards. In order to qualify the system for the broad spectrum of challenges it will face in the inpatient setting, this study will test the ability of the new integrated configuration of the system (the GlucoSTAT) to control PG in subjects with extremes of insulin sensitivity. The first goal of this study is to test the safety and efficacy of the control system in insulin sensitive subjects with type 1 diabetes. The second goal of this study is to test the safety and efficacy of the control system in subjects with type 2 diabetes and substantial insulin resistance (TDD > 0.75 u/kg/day, with up to 3 subjects with a TDD > 2 u/kg/day).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes, Type 2 Diabetes Treated With Insulin
Keywords
closed loop, insulin, dextrose

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
GlucoSTAT
Arm Type
Experimental
Arm Description
Type 1 diabetes and Type 2 diabetes with a total daily dose (TDD) of insulin that is > 0.75 u/kg or ≥ 2 u/kg.
Intervention Type
Device
Intervention Name(s)
GlucoSTAT
Other Intervention Name(s)
Closed-loop blood glucose control
Intervention Description
Closed-loop blood glucose control using intravenous insulin and dextrose
Primary Outcome Measure Information:
Title
Average plasma glucose over the closed-loop control period
Description
Average plasma glucose
Time Frame
every 15 minutes for 8.5 hours
Secondary Outcome Measure Information:
Title
Number of carbohydrate interventions needed to treat hypoglycemia
Description
The number of times that carbohydrates were consumed in response to hypoglycemia throughout the 8.5 hour experiment
Time Frame
8.5 hour experiment duration
Title
Grams of carbohydrates needed to treat hypoglycemia
Description
The amount of carbohydrates consumed in response to hypoglycemia throughout the 8.5 hour experiment
Time Frame
8.5 hour experiment duration
Title
Carbohydrate content and total calories of consumed lunch meal
Description
The amount of carbohydrates and total calories the subject consumed during their provided lunch
Time Frame
during 30 minute meal
Title
Insulin dosing (u/kg)
Description
Total amount of insulin delivered by the GlucoSTAT during the experiment
Time Frame
8.5 hour experiment duration
Title
Dextrose dosing (g/kg)
Description
Total amount of dextrose delivered by the GlucoSTAT during the experiment
Time Frame
8.5 hour experiment duration

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 1 diabetes: Age 18 years or older with clinical type 1 diabetes for at least one year. Diabetes currently managed using an insulin infusion pump and rapid- or very-rapid-acting insulins including insulin aspart (NovoLog or Fiasp), insulin lispro (Humalog), and insulin glulisine (Apidra). Total daily dose (TDD) of insulin that is ≤ 1 U/kg Prescription medication regimen stable for at least 1 month. Informed consent obtained before any trial-related activities. Type 2 diabetes: Age 18 years or older with clinical type 2 diabetes for at least 1 year. Diabetes currently managed using NPH as the basal insulin, which may be supplemented with regular or rapid-acting insulin and/or other anti-diabetic drugs. Total daily dose (TDD) of insulin that is > 0.75 u/kg Our goal is to have up to 3 T2D subjects with a TDD > 2 u/kg Prescription medication regimen stable for at least 1 month. Informed consent obtained before any trial-related activities. Exclusion Criteria: Unable to provide informed consent. Unable to comply with study procedures. Current participation in another diabetes-related clinical trial that, in the judgement of the principal investigator, will compromise the results of this study or the safety of the participant Use of a long-acting insulin (in type 1 diabetes subjects) or a long-acting insulin other than NPH (in type 2 diabetes subjects), including insulin glargine (Lantus), insulin detemir (Levemir), insulin degludec (Tresiba), or ultra-lente. Pregnancy (positive urine HCG), breast feeding, plan to become pregnant in the immediate future, or sexually active without use of contraception. Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be susceptible to RF interference. Established history of latex, adhesive, or tape allergy that must be used in the study Inadequate venous access as determined by study nurse or physician at time of screening. Employed by, or having immediate family members employed by Beta Bionics, or being directly involved in conducting the clinical trial, or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial. A condition that in the opinion of the investigator could interfere with the safe completion of the study. Conditions to be considered by the investigator may include the following: Alcohol or drug abuse Use of prescription drugs that may dull the sensorium, reduce sensitivity to symptoms of hypoglycemia, or hinder decision making during the period of participation in the study Renal failure Coronary artery disease that is not stable with medical management, including unstable angina, angina that prevents moderate exercise (e.g. climbing a flight of stairs) despite medical management, or within the last 12 months before screening a history of myocardial infarction, percutaneous coronary intervention, enzymatic lysis of a presumed coronary occlusion, or coronary artery bypass grafting Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV History of TIA or stroke in the last 12 months Untreated or inadequately treated mental illness
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steven J Russell, MD, PhD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT

We'll reach out to this number within 24 hrs